ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million
21 Oct, 2021
– A company addressing the most common and costly venous access complications has closed on a Series B round of financing.
– TVM Capital Life Science led the round with a $15m commitment, with existing investors also participating.
– The company has developed a proprietary biomaterial platform that is both hydrophilic and lubricious, and has incorporated this material into two commercially-available venous access devices, the HydroPICC® Peripherally Inserted Central Catheter and HydroMID™ Midline Catheter.
– In vitro studies have shown that this biomaterial technology results in an average of 97% less thrombus accumulation on its surface compared to a standard polyurethane catheter.*